华东医药股份有限公司 关于2022年限制性股票激励计划首次授予限制性股票第三个解除限售期 解除限售股份上市流通的提示性公告

Core Viewpoint - The company has successfully achieved the conditions for the third unlock period of its 2022 restricted stock incentive plan, allowing 77 eligible participants to unlock a total of 1.27512 million shares, representing 0.07% of the company's total share capital, with the unlock date set for December 10, 2025 [2][33]. Summary by Sections Incentive Plan Approval and Execution - The company held its 11th Board of Directors' fifth meeting on November 20, 2025, where it approved the achievement of the third unlock conditions for the 2022 restricted stock incentive plan [2][8]. - The initial approval process for the incentive plan included multiple meetings and independent opinions confirming its alignment with the company's long-term development [4][5]. Unlock Conditions and Share Details - The third unlock period for the restricted stock began on November 17, 2025, and allows for a 40% unlock of the initially granted shares [18][19]. - The total number of shares eligible for unlock is 1.27512 million, with 77 participants meeting the conditions [33]. Adjustments and Repurchases - The company has made adjustments to the incentive plan, including the repurchase of shares from participants who no longer qualify due to personal reasons or performance issues, totaling 9.78 million shares [19][20]. - The repurchase price for the shares has been adjusted based on the company's profit distribution plan, ensuring compliance with regulatory requirements [23][24]. Future Share Structure Changes - The company anticipates changes in its share structure following the unlock of restricted stocks, although the exact impact will be confirmed by the relevant regulatory bodies [35][36].